Celcuity, Inc. (NASDAQ:CELC) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Celcuity, Inc. (NASDAQ:CELC) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $105.25.

CELC has been the topic of several analyst reports. Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a report on Sunday, October 26th. Wolfe Research began coverage on shares of Celcuity in a report on Tuesday, November 18th. They set an “outperform” rating and a $110.00 price objective for the company. Craig Hallum raised their target price on shares of Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Jefferies Financial Group boosted their target price on shares of Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. Finally, Wells Fargo & Company assumed coverage on shares of Celcuity in a report on Friday, December 12th. They set an “overweight” rating and a $126.00 price target for the company.

Insider Activity at Celcuity

In other news, Director Richard E. Buller sold 3,000 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $105.69, for a total value of $317,070.00. Following the completion of the sale, the director directly owned 6,760 shares of the company’s stock, valued at approximately $714,464.40. This represents a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David Dalvey sold 20,000 shares of the firm’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the sale, the director owned 90,000 shares in the company, valued at approximately $10,802,700. The trade was a 18.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 15.77% of the stock is owned by corporate insiders.

Institutional Trading of Celcuity

A number of hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC increased its holdings in shares of Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares during the period. Meeder Asset Management Inc. acquired a new stake in Celcuity during the fourth quarter worth about $42,000. Ogorek Anthony Joseph NY ADV acquired a new stake in Celcuity during the third quarter worth about $27,000. US Bancorp DE increased its stake in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares during the period. Finally, NBC Securities Inc. acquired a new position in Celcuity in the 4th quarter valued at approximately $99,000. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Performance

CELC opened at $105.71 on Thursday. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. The company has a market cap of $4.89 billion, a PE ratio of -28.80 and a beta of 0.36. The stock has a 50-day moving average of $105.56 and a 200-day moving average of $79.69. Celcuity has a 52-week low of $7.57 and a 52-week high of $120.32.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.